Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Jaguar Health's Enterprise Value for the quarter that ended in Jun. 2026 was $27.39 Mil.
Jaguar Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health EV-to-EBIT Related Terms
Jaguar Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Jaguar Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jaguar Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Jaguar Health's EV-to-EBIT falls into.
Jaguar Health's current Enterprise Value is $15.91 Mil.
Jaguar Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (JAGX) has a EV-to-EBIT of -0.46 as of Sep. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #999999 out of 364 companies in the Biotechnology industry.
Is Jaguar Health's EV-to-EBIT too high?
Jaguar Health's current EV-to-EBIT is -0.46. Based on the distribution chart, Jaguar Health ranks #999999 out of 364 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jaguar Health has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's EV-to-EBIT compare to APVO and GRI?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #999999 out of 364 companies for EV-to-EBIT. This places Jaguar Health in the lower half of its industry. The industry median EV-to-EBIT is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.69, based on 364 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jaguar Health and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaguar Health's current EV-to-EBIT is -0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Based on GuruFocus' analysis, Jaguar Health (JAGX) is currently considered Possible Value Trap. The stock's GF Value™ is $112.68, compared to a current price of $0.60 — trading 99.5% below its estimated fair value. The current EV-to-EBIT is -0.46. Jaguar Health's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Jaguar Health (JAGX), the current EV-to-EBIT is -0.46 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jaguar Health (JAGX) Overvalued in 2026?
Based on GuruFocus' analysis, Jaguar Health stock appears to be undervalued.
The current stock price of $0.60 is trading 99.5% below its estimated GF Value™ of $112.68.
GuruFocus considers Jaguar Health to be Possible Value Trap.
Key valuation signals for JAGX:
EV-to-EBIT: -0.46
GF Value™: $112.68 vs. price of $0.60 (99.5% below fair value)
No single metric tells the full story. See the JAGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
38GF Score
Get the complete analysis for JAGX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
